Kynurenine Concentrations During Pregnancy in Women With or Without Chronic Kidney Disease - A Prospective Multicenter Study
- Sponsor
- CHU de Reims
- Study ID
- NCT07411937
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Chronic Kidney Diseases
- Preeclampsia
- Pregnancy
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Blood sampling — OTHERA 14ml blood sample will be collected during the first second and third trimesters of pregnancy and at 2 months (+ 1 month post partum)
Study Details
Chronic kidney disease (CKD) affects more than 10% of the population worldwide and represents the second most important risk factor for preeclampsia, a life-threatening complication of pregnancy responsible for approximately 80,000 maternal and 500,000 perinatal deaths each year. Experimental studies have suggested a causal link between CKD, relative kynurenine deficiency during pregnancy, and preeclampsia development. Kynurenine, a tryptophan metabolite, plays a central role at the materno-fetal interface, supporting placental energy production, maternal-fetal immune tolerance, and placental perfusion. This study will prospectively assess and compare longitudinal kynurenine concentrations in pregnant women with and without CKD, and evaluate their associations with maternal and fetal outcomes.
Key Dates
- First listed
- Feb 17, 2026
- Start date
- Mar 31, 2026
- Status verified
- Jan 2026
- Primary completion
- Sep 30, 2028
- Completion
- May 31, 2029
Study Design
- Enrollment
- 204 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Other: Women with chronic kidney disease
- Other: Women without chronic kidney disease
Primary Outcome Measure
Kynurenine concentration at the 3rd trimester (32±1 weeks) in women with and without CKD [ Time Frame: 32±1 weeks ]
Central Contacts
- Vincent DUPONT03 26 78 76 41
Related Studies
- Effects of Oncological Treatment During Pregnancy on Mother and ChildRecruiting · University Hospital, Gasthuisberg · Camden, New Jersey
- Prenatal Exposure Effects Psychophysiology StudyEnrolling By Invitation · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
- Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With PhenylketonuriaRecruiting · Emory University · Atlanta, Georgia
- BLOOM: Biological Legacy of Origin in Mother-Infant DyadsRecruiting · University of Miami · Miami, Florida